109162 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone Phosphorothioates
COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
#3002Therapeutic micro RNA targets in chronic pulmonary diseases
#3003COMPOSITIONS AND METHODS FOR MODULATING BDNF EXPRESSION
#3004Compositions and methods for modulating hemoglobin gene family expression
#3005Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
#3006Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
#3007Immunostimulatory sequence oligonucleotides and methods of using the same
#3008Compositions and methods for modulating apolipoprotein (a) expression
#3009Compositions and methods for modulating apolipoprotein C-III expression
#3010Conjugated antisense compounds and their use
#3011Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
#3012Micro-RNA inhibitors and their uses in disease
#3013Methods and compositions involving immunostimulatory oligodeoxynucleotides
#3014Method for constructing functional nucleic acid molecule, and nucleic acid combination to be used in said method
#3015Compositions and Methods for Inhibiting Expression of RRM2 Genes
#3016RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
#3017Compositions and methods for inhibiting expression of the ALAS1 gene
#3018Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions
#3019MicroRNA compounds and methods for modulating miR-122
#3020Compositions and methods for gene silencing
#3021Therapeutic agent for treating -associated disease, method for killing parasites, and use thereof
#3022Antisense modulation of GCGR expression
#3023Compositions and methods for modulating UTRN expression
#3024Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
#3025Methods and compositions for modulating alpha-1-antitrypsin expression
#3026Peptide-conjugated oligonucleotide therapeutic and method of making and using same
#3027Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
#3028Targeting micrornas for the treatment of fibrosis
#3029Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA
#3030Glycoconjugates of RNA interference agents
#3031Antisense conjugates for decreasing expression of DMPK
#3032Double-stranded oligonucleotides
#3033COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB
#3034Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#3035Targeting MicroRNAs for metabolic disorders
#3036METHODS AND COMPOSITIONS FOR MODULATING FACTOR VII EXPRESSION
#3037Compounds and methods for enhanced cellular uptake
#3038COMPOSITIONS AND METHODS FOR MODULATION OF IKBKAP SPLICING
#3039Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
#3040Oligomer-conjugate complexes and their use
#3041Modifications for antisense compounds
#3042Method for prevention of colectomy
#3043Modulation of T cell signaling threshold and T cell sensitivity to antigens
#3044Anti-connexin compounds targeted to connexins and methods of use thereof
#3045Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression
#3046Reduced size self-delivering RNAi compounds
#3047Modulation of hepatitis B virus (HBV) expression
#3048MicroRNA compounds and methods for modulating miR-122
#3049Compositions and methods for inhibiting expression of the PCSK9 gene
#3050Antisense nucleic acids
#3051Conjugated antisense compounds and their use
#3052Compositions and methods for inhibiting expression of factor VII gene
#3053Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#3054Compositions and methods for prognosis and treatment of prostate cancer
#3055Modulation of signal transducer and activator of transcription 3 (STAT3) expression
#3056Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#3057Selective antisense compounds and uses thereof
#3058COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION AND USES THEREOF
#3059Methods and compounds useful in conditions related to repeat expansion
#3060RNA interference in skin indications
#3061RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
#3062Stabilized STAT3 decoy oligonucleotides and uses therefore
#3063Therapeutic compositions
#3064Modulation of TMPRSS6 expression
#3065Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof
#3066Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
#3067Control of whole body energy homeostasis by microRNA regulation
#3068Antisense antiviral compound and method for treating influenza viral infection
#3069Complement antagonists and uses thereof
#3070Antisense design
#3071Tricyclo-phosphorothioate DNA
#3072Compositions and methods for inhibiting expression of the HAMP gene
#3073Immune tolerance inducer
#3074Modified RNAi agents
#3075Exon skipping therapy for dystrophic epidermolysis bullosa
#3076Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
#3077Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP
#3078Preventive or therapeutic agent for fibrosis
#3079Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
#3080Anti-clusterin monotherapy for cancer treatment
#3081Custirsen treatment with reduced toxicity
#3082Methods of treating colorectal cancer
#3083Modulation of transthyretin expression
#3084Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
#3085Activation of quiescent stem cells
#3086Compositions and methods for inhibiting expression of a gene from the Ebola virus
#3087Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
#3088Clusterin antisense therapy for treatment of cancer
#3089Modulation of HSP47 expression
#3090Antisense modulation of PTP1B expression
#3091Methods for modulating factor 12 expression
#3092MicroRNA inhibitors
#3093Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#3094Methods for modulating kallikrein (KLKB1) expression
#3095Targeting microRNAs for the treatment of liver cancer
#3096Methods for modulating kallikrein (KLKB1) expression
#3097Immunostimulatory oligodeoxynucleotides
#3098Immunostimulatory oligodeoxynucleotides
#3099Compositions and methods for inhibiting expression of TMPRSS6 gene
#3100Modulation of angiopoietin-like 3 expression
#3101Immunostimulatory oligodeoxynucleotides
#3102Modulators of miR-323-3p for the prevention or treatment of rheumatoid arthritis
#3103Connective tissue growth factor antisense oligonucleotides
#3104Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#3105Spinal muscular atrophy treatment via targeting SMN2 catalytic core
#3106Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#3107Suppressors of CpG oligonucleotides and methods of use
#3108Nucleic acid/polysaccharide complex
#3109Oligonucleotide derivative, oligonucleotide derivative-containing pharmaceutical composition for treatment and pharmaceutical composition for diagnosis, and oligonucleotide derivative for regulation of miRNA function
#3110Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
#3111Chimeric immunomodulatory compounds and methods of using the same-IV
#3112Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#3113Microrna (miRNA) and downstream targets for diagnostic and therapeutic purposes
#3114C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
#3115Antisense compounds targeting genes associated with usher syndrome
#3116Method of treating cancer by inhibition of DNA repair proteins
#3117RNA interference in dermal and fibrotic indications
#3118Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#3119Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
#3120Modulation of hepatitis B virus (HBV) expression
#3121Modulation of androgen receptor expression
#3122Organic compositions to treat Beta-ENaC-related diseases
#3123Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
#3124Methods for treatment of alport syndrome
#3125TRPM-2 antisense therapy
#3126Methods of X-aptamer generation and compositions thereof
#3127RNA interference mediated inhibition of isocitrate dehydrogenase (IDH1) gene expression
#3128Antisense modulation of fibroblast growth factor receptor 4 expression
#3129Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#3130RNAi modulation of ApoB and uses thereof
#3131Compositions and methods for increasing erythropoietin (EPO) production
#3132Antimir-451 for the treatment of polycythemias
#3133Modulation of alpha synuclein expression
#3134Compositions and methods for characterizing and treating muscular dystrophy
#3135Inhibitors of the miR-15 family of micro-RNAs
#3136Oligonucleotide-based inhibitors comprising locked nucleic acid motif
#3137Methods for modulating factor 12 expression
#31385′-end derivatives
#3139Modulation of apolipoprotein C-III expression
#3140Serpinc1 iRNA compositions and methods of use thereof
#3141Modified iRNA agents
#3142Oligonucleotide compositions with enhanced efficiency
#3143Compositions and their uses directed to huntingtin
#3144Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
#3145Antisense modulation of fibroblast growth factor receptor 4 expression
#3146Compositions and methods for inhibiting expression of Eg5 gene
#3147RNAi modulation of SCAP and therapeutic uses thereof
#3148Gene silencing by single-stranded polynucleotides
#3149Micro-RNA family that modulates fibrosis and uses thereof
#3150Micro-RNA family that modulates fibrosis and uses thereof
#3151Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
#3152Modifications for antisense compounds
#3153Short interfering ribonucleic acid (siRNA) for oral administration
#3154RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#3155Antisense nucleic acids
#3156Inhibition of PCSK9 through RNAi
#3157Micro-RNA family that modulates fibrosis and uses thereof
#3158Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
#3159Compositions and their uses directed to huntingtin
#3160TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF
#3161Inhibitor of HMGB protein-mediated immune response activation, and screening method
#3162In vivo gene silencing by chemically modified and stable siRNA
#3163Selective inhibition of polyglutamine protein expression
#3164RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#3165Compounds and methods for modulating expression of DGAT2
#3166Nuclease resistant double-stranded ribonucleic acid
#3167RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
#3168Antisense modulation of GCCR expression
#3169Immunostimulatory sequence oligonucleotides and methods of using the same
#3170Nucleic acid functionalized nanoparticles for therapeutic applications
#3171Antisense modulation of GCGR expression
#3172Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
#3173MicroRNA as a cancer progression predictor and its use for treating cancer
#3174Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
#3175Therapeutic antisense oligonucleotide compositions for the treatment of inflammatory bowel disease
#3176Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#3177Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
#3178Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
#3179Compositions and methods for inhibiting expression of CD45 gene
#3180METHODS AND COMPOSITIONS USEFUL IN TREATMENT OF DISEASES OR CONDITIONS RELATED TO REPEAT EXPANSION
#3181MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION
#3182Modulation of growth hormone receptor expression and insulin-like growth factor expression
#3183MODULATION OF CETP EXPRESSION
#3184Composition For Delivery Of Genetic Material
#3185Selective reduction of allelic variants
#3186Double-stranded oligonucleotides
#3187miR-150 for the treatment of blood disorders
#3188Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#3189Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
#3190Lipid formulated dsRNA targeting the PCSK9 gene
#3191DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#3192Modulation of Hepatitis B virus (HBV) expression
#3193Anti-sense oligonucleotides targeted against exon 9 of IL-23Rα gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases
#3194Modulation of forkhead box O1A expression
#3195DOSING REGIMENS FOR TREATING AND PREVENTING OCULAR DISORDERS USING C-RAF ANTISENSE
#3196Compositions and methods for inhibiting expression of XBP-1 gene
#3197Modulation of angiopoietin-like 3 expression
#3198Compositions and methods for inhibiting expression of Eg5 and VEGF genes
#3199Method of treating inflammatory arthropathies with supressors of CPG oligonucleotides
#3200MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#3201Organic compositions to treat Beta-ENaC-related diseases
#3202GNAQ targeted dsRNA compositions and methods for inhibiting expression
#3203RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#3204Compositions and methods for inhibiting gene expression of hepatitis B virus
#3205Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
#3206Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
#3207Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
#3208Oral delivery of therapeutically effective LNA oligonucleotides
#3209TRPM-2 antisense therapy
#3210LNA OLIGONUCLEOTIDES AND THE TREATMENT OF CANCER
#3211Compositions and methods for inhibiting expression of the HAMP gene
#3212COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
#3213MODULATION OF APOLIPOPROTEIN(A) EXPRESSION
#3214Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
#3215Targeting microRNAs for the treatment of liver cancer
#3216MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#3217Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
#3218Modulation of glucagon receptor expression
#3219RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3
#3220Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
#3221TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY
#3222Proinflammatory nucleic acids
#3223TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
#3224Antisense modulation of PTP1B expression
#3225Stabilized STAT3 decoy oligonucleotides and uses therefor
#3226Method of inhibiting miR-33 using a modified oligonucleotide
#3227Modulation of eIF4E expression
#3228Antisense oligonucleotides against cPLA, compositions and uses thereof
#3229Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
#3230Modulation of signal transducer and activator of transcription 3 (STAT3)expression
#3231MODULATION OF TTC39 EXPRESSION TO INCREASE HDL
#3232Antisense molecules and methods for treating pathologies
#3233Oligomeric compounds for the modulation of HIF-1A expression
#3234Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
#3235Single molecule nucleic acid nanoparticles
#3236Suppressors of CpG oligonucleotides and methods of use
#3237RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
#3238MicroRNA as a cancer progression predictor and its use for treating cancer
#3239Oligonucleotide complex compositions and methods of use as gene alteration tools
#3240Modulation of huntingtin expression
#3241RNAi modulation of APOB and uses thereof
#3242TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)
#3243COMPOSITIONS AND METHODS FOR DELIVERING RNAI USING APOE
#3244MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 1 EXPRESSION
#3245Compositions and methods for prognosis and treatment of prostate cancer
#3246Chimeric immunomodulatory compounds and methods of using the same-IV
#3247Compositions and methods for inhibiting expression of transthyretin
#3248AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#3249COMBINATION MOTIF IMMUNE STIMULATORY OLIGONUCLEOTIDES WITH IMPROVED ACTIVITY
#3250Methods for slowing familial ALS disease progression
#3251MODULATION OF FACTOR 7 EXPRESSION
#3252METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE
#3253COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS
#3254Immunostimulatory oligonucleotides
#3255COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR
#3256Compositions and methods for inhibiting expression of factor VII gene
#3257Antisense oligonucleotide modulation of STAT3 expression
#3258RNAi probes targeting cancer-related proteins
#3259Antisense oligonucleotides
#3260MODULATION OF SGLT-2 EXPRESSION
#3261Compositions and methods for modulation of SMN2 splicing in a subject
#3262ANTIVIRAL OLIGONUCLEOTIDES
#3263MicroRNA inhibitors comprising locked nucleotides
#3264ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA
#3265Lipid formulation
#3266SPARC ANTISENSE COMPOSITIONS AND USES THEREOF
#3267MicroRNA-24
#3268Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (mi145) and micro-RNA 212 (miR212)
#3269COMPOSITIONS COMPRISING IMMUNOSTIMULATORY NUCLEIC ACIDS AND RELATED METHODS
#3270Method for modulating responsiveness to steroids
#3271TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE
#3272Chemical modification of short small hairpin RNAs for inhibition of gene expression
#3273Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
#3274Compositions and methods for inhibiting expression of RRM2 genes
#3275Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#3276MODULATION OF EIF4E-BP2
#3277ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION
#3278MODULATION OF TRANSTHYRETIN EXPRESSION
#3279CHEMICAL MODIFICATIONS MOTIFS FOR MIRNA INHIBITORS AND MIMETICS
#3280Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating B cell neoplasm
#3281SOLUBLE THF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
#3282Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
#3283Inhibitors of heat shock RNA
#3284Compositions and Methods for Inhibiting Expression of Eg5 Gene
#3285ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES THEREOF IN MEDICAL FIELD
#3286Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
#3287Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
#3288dsRNA for treating viral infection
#3289Lipophilic polynucleotide conjugates
#3290Organic compositions to treat Beta-ENaC-related diseases
#3291Targeting MicroRNAs for metabolic disorders
#3292Antisense oligomers targeting PCSK9
#3293Methods for enhancing utrophin production via inhibition of microRNA
#3294Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#3295RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
#3296Treatment of neurological disorders
#3297Potent anti APOB antisense compounds
#3298Organic compositions to treat beta-ENaC-related diseases
#3299Organic compositions to treat Beta-ENaC-related diseases
#3300Modulation of STAT 6 expression